ASMPT (00522) completes strategic options review and retains SMT Solutions segment
ASMPT (00522) announced that its board of directors has concluded that retaining the SMT Solutions segment as part of the ASMPT Group is in the best interests of the company and its shareholders.
Accordingly, the strategic options review of the SMT Solutions segment initiated in January 2026 has been completed.
ASMPT (00522) announced that its board of directors has concluded that retaining the SMT Solutions segment as part of the ASMPT Group is in the best interests of the company and its shareholders.
Accordingly, the strategic options review for the SMT Solutions segment, which was initiated in January 2026, has been completed.
After a comprehensive review of a range of strategic options, including a sale, joint venture, spin-off, listing, and retaining the business within the group, the board believes that the growth and profitability prospects of the SMT Solutions segment, as part of ASMPT, will provide opportunities to create sustainable long-term shareholder value.
Bassel Haddad, Chief Executive Officer of ASMPT Group, said: "Since joining ASMPT in August, I have continued to witness how artificial intelligence (AI) is bringing new opportunities to ASMPT's business portfolio. For our SMT Solutions segment, AI-driven demand is propelling the business's financial performance to a new level. With the future direction of SMT within ASMPT further clarified, we will focus on disciplined execution, fully realizing its potential, and creating sustainable long-term value for shareholders."
Related Articles

Filling a clinical gap! GRAND PHARMA (00512) CBT-001 significantly controls pterygium lesions, deepening its presence in the innovative ophthalmic drug track and targeting a blue ocean market worth tens of billions

Hinova Pharmaceuticals (688302.SH) Signs Exclusive Licensing Agreement to Advance Overseas Market Development of HP570

GRAND PHARMA (00512): Global Innovative Ophthalmic Drug CBT-001 for Pterygium Meets Primary Clinical Endpoint in International Multicenter Phase III Clinical Trial
Filling a clinical gap! GRAND PHARMA (00512) CBT-001 significantly controls pterygium lesions, deepening its presence in the innovative ophthalmic drug track and targeting a blue ocean market worth tens of billions

Hinova Pharmaceuticals (688302.SH) Signs Exclusive Licensing Agreement to Advance Overseas Market Development of HP570

GRAND PHARMA (00512): Global Innovative Ophthalmic Drug CBT-001 for Pterygium Meets Primary Clinical Endpoint in International Multicenter Phase III Clinical Trial






